SMJ articles in the category "bisphosphonates"

Original Article

Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates

Objective:This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate in women who switched from once-weekly bisphosphonates and had reported GI symptoms with their previous weekly bisphosphonate regimen.Methods:Postmenopausal women currently taking a weekly bisphosphonate switched to 150 mg monthly ibandronate. At…

Posted in: bisphosphonates 5 Osteoporosis 29

Review Article

Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies

Numerous studies have analyzed data from administrative claims databases to determine persistence and compliance with bisphosphonate therapy for osteoporosis; several of these studies have also examined how persistence and compliance with therapy affect fracture outcomes. All of the studies included in this review demonstrated that patients who were persistent or…

Posted in: bisphosphonates 5 Osteoporosis 29 persistence 3

Original Article

Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting

Background: The effectiveness of chronic therapies can be compromised by poor adherence and persistence. Materials and Methods: Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene. Drug utilization parameters…

Posted in: adherence 10 bisphosphonates 5 Osteoporosis 29 persistence 3 raloxifene 2

Original Article

Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting

Background:The effectiveness of chronic therapies can be compromised by poor adherence and persistence. Materials and Methods:Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene. Drug utilization parameters were evaluated…

Posted in: adherence 10 bisphosphonates 5 Osteoporosis 29 persistence 3 raloxifene 2

Review Article

Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis

One-year vertebral fracture risk reduction from clinical trials in adults with postmenopausal or glucocorticoid-induced osteoporosis is reviewed. Data were obtained by conducting a literature search of osteoporosis medications using the MEDLINE database, bibliographies of selected citations, and recent meeting abstracts. The methodologic quality of the trials was assessed using recently…

Posted in: bisphosphonates 5 Osteoporosis 29 vertebral fracture 2
SMA Menu